ArticleThe New England journal of medicine2021
A Large, Simple Trial Leading to Complex Questions.
Article in The New England journal of medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Remdesivir for the treatment of COVID-19.The Cochrane database of systematic reviews · 2023Pooled it
- Remdesivir for the treatment of COVID-19.The Cochrane database of systematic reviews · 2021Pooled it
- Major Update: Remdesivir for Adults With COVID-19 : A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points.Annals of internal medicine · 2021Pooled it
- How to build a better clinical trial ecosystem for future infectious disease emergencies in Japan: Findings from a narrative review and stakeholder meetings.Global health & medicine · 2025Review
- The impact of remdesivir on SARS-CoV-2 evolution in vivo.JCI insight · 2025Article
- XNAzymes targeting the SARS-CoV-2 genome inhibit viral infection.Nature communications · 2022Article
- Identification and Development of Therapeutics for COVID-19.mSystems · 2021Article
- Clinical trials with antiviral drugs against COVID-19: some progress and many shattered hopes.Environmental microbiology · 2021Review
- SARS-CoV-2-host proteome interactions for antiviral drug discovery.Molecular systems biology · 2021Article
- Evaluating the Clinical Outcomes of Remdesivir Among Patients Admitted With COVID-19 in a Tertiary Care Hospital.Cureus · 2021Article
- Playing vaccine roulette: Why the current strategy of staking everything on Covid-19 vaccines is a high-stakes wager.Vaccine · 2021Article
- On aerosol transmission of SARS-CoV-2.Journal of family medicine and primary care · 2021Article
- What we learned in the past year in managing our COVID-19 patients in intensive care units?World journal of critical care medicine · 2021Review
- Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality.Open forum infectious diseases · 2021Article
- Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19.JAMA network open · 2021Article
- Reply to Yan and Muller, "Remdesivir for COVID-19: Why Not Dose Higher?"Antimicrobial agents and chemotherapy · 2021Article
- Article
- Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19.JAMA network open · 2021Article
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.